{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:43:43Z","timestamp":1791045823550,"version":"4.1.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"Importance<\/jats:title>Clinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the effectiveness of a sequential and adaptive intervention strategy for individuals at ultrahigh risk of psychosis.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia. Individuals aged 12 to 25 years who were seeking treatment and met criteria for ultrahigh risk of psychosis according to the Comprehensive Assessment of At-Risk Mental States were recruited between April 2016 and January 2019. Of 1343 individuals considered, 342 were recruited.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Step 1: 6 weeks of support and problem solving (SPS); step 2: 20 weeks of cognitive-behavioral case management (CBCM) vs SPS; and step 3: 26 weeks of CBCM with fluoxetine vs CBCM with placebo with an embedded fast-fail option of \u03c9-3 fatty acids or low-dose antipsychotic medication. Individuals who did not remit progressed through these steps; those who remitted received SPS or monitoring for up to 12 months.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Global Functioning: Social and Role scales (primary outcome), Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Montgomery-\u00c5sberg Depression Rating Scale, quality of life, transition to psychosis, and remission and relapse rates.<\/jats:p><\/jats:sec>Results<\/jats:title>The sample comprised 342 participants (198 female; mean [SD] age, 17.7 [3.1] years). Remission rates, reflecting sustained symptomatic and functional improvement, were 8.5%, 10.3%, and 11.4% at steps 1, 2, and 3, respectively. A total of 27.2% met remission criteria at any step. Relapse rates among those who remitted did not significantly differ between SPS and monitoring (step 1: 65.1% vs 58.3%; step 2: 37.7% vs 47.5%). There was no significant difference in functioning, symptoms, and transition rates between SPS and CBCM and between CBCM with fluoxetine and CBCM with placebo. Twelve-month transition rates to psychosis were 13.5% (entire sample), 3.3% (those who ever remitted), and 17.4% (those with no remission).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this sequential multiple assignment randomized trial, transition rates to psychosis were moderate, and remission rates were lower than expected, partly reflecting the ambitious criteria set and challenges with real-world treatment fidelity and adherence. While all groups showed mild to moderate functional and symptomatic improvement, this was typically short of remission. While further adaptive trials that address these challenges are needed, findings confirm substantial and sustained morbidity and reveal relatively poor responsiveness to existing treatments.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02751632<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.1947","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T15:34:05Z","timestamp":1687966445000},"page":"875","source":"Crossref","is-referenced-by-count":48,"title":["A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis"],"prefix":"10.1001","volume":"80","author":[{"given":"Patrick D.","family":"McGorry","sequence":"first","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mei","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Paul","family":"Amminger","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hok Pan","family":"Yuen","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kerr","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Spark","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Wallis","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Polari","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Orygen Specialist Program, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Baird","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Buccilli","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Jane A.","family":"Dempsey","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Formica","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Krcmar","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia L.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohannes","family":"Mebrahtu","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlan","family":"Ruslins","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Street","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Wannan","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Dixon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Loewy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara A.","family":"Niendam","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Shumway","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby","family":"Nelson","sequence":"additional","affiliation":[{"name":"Orygen, Melbourne, Victoria, Australia"},{"name":"Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"yoi230041r1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/schbul\/22.2.283","article-title":"Monitoring and care of young people at incipient risk of psychosis.","volume":"22","author":"Yung","year":"1996","journal-title":"Schizophr Bull"},{"issue":"1","key":"yoi230041r2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41537-020-00117-0","article-title":"Progression from being at-risk to psychosis: next steps.","volume":"6","author":"Addington","year":"2020","journal-title":"NPJ Schizophr"},{"key":"yoi230041r3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.schres.2020.12.026","article-title":"Intervention strategies for ultrahigh risk for psychosis: progress in delaying the onset and reducing the impact of first-episode psychosis.","volume":"228","author":"McGorry","year":"2021","journal-title":"Schizophr Res"},{"key":"yoi230041r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2021.102005","article-title":"Preventive interventions for individuals at ultra high risk for psychosis: an updated and extended meta-analysis.","volume":"86","author":"Mei","year":"2021","journal-title":"Clin Psychol Rev"},{"issue":"3","key":"yoi230041r5","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17r12053","article-title":"Interventions and transition in youth at risk of psychosis: a systematic review and meta-analyses.","volume":"81","author":"Devoe","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi230041r6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/wps.v17.2","article-title":"Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis.","volume":"17","author":"Davies","year":"2018","journal-title":"World Psychiatry"},{"issue":"1","key":"yoi230041r7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamapsychiatry.2016.2902","article-title":"Effect of ?-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial.","volume":"74","author":"McGorry","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi230041r8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4088\/JCP.12m07785","article-title":"Randomized controlled trial of interventions for young people at ultrahigh risk of psychosis: twelve-month outcome.","volume":"74","author":"McGorry","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi230041r9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/eip.2019.13.issue-1","article-title":"Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis.","volume":"13","author":"Devoe","year":"2019","journal-title":"Early Interv Psychiatry"},{"issue":"4","key":"yoi230041r10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/schbul\/sbx139","article-title":"Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis.","volume":"44","author":"Devoe","year":"2018","journal-title":"Schizophr Bull"},{"key":"yoi230041r11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fpsyt.2018.00187","article-title":"Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis.","volume":"9","author":"Davies","year":"2018","journal-title":"Front Psychiatry"},{"issue":"2","key":"yoi230041r12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/eip.2019.13.issue-2","article-title":"Interventions and social functioning in youth at risk of psychosis: a systematic review and meta-analysis.","volume":"13","author":"Devoe","year":"2019","journal-title":"Early Interv Psychiatry"},{"issue":"11","key":"yoi230041r13","article-title":"Interventions for prodromal stage of psychosis.","volume":"2019","author":"Bosnjak Kuharic","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"yoi230041r14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamapsychiatry.2013.1909","article-title":"Prediction of functional outcome in individuals at clinical high risk for psychosis.","volume":"70","author":"Carri\u00f3n","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"yoi230041r15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/eip.2018.12.issue-3","article-title":"Staged treatment in early psychosis: a sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.","volume":"12","author":"Nelson","year":"2018","journal-title":"Early Interv Psychiatry"},{"issue":"3","key":"yoi230041r16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.biopsych.2019.08.030","article-title":"The NEURAPRO biomarker analysis: long-chain omega-3 fatty acids improve 6-month and 12-month outcomes in youths at ultrahigh risk for psychosis.","volume":"87","author":"Amminger","year":"2020","journal-title":"Biol Psychiatry"},{"issue":"10","key":"yoi230041r17","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/sim.v24:10","article-title":"An experimental design for the development of adaptive treatment strategies.","volume":"24","author":"Murphy","year":"2005","journal-title":"Stat Med"},{"issue":"1","key":"yoi230041r18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.schres.2015.11.026","article-title":"Declining transition rates to psychotic disorder in \u201cultrahigh risk\u201d clients: investigation of a dilution effect.","volume":"170","author":"Hartmann","year":"2016","journal-title":"Schizophr Res"},{"issue":"3","key":"yoi230041r19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/schbul\/sbm015","article-title":"Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?","volume":"33","author":"Yung","year":"2007","journal-title":"Schizophr Bull"},{"issue":"10","key":"yoi230041r20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/eip.v16.10","article-title":"Baseline data of a sequential multiple assignment randomized trial (STEP study).","volume":"16","author":"Hartmann","year":"2022","journal-title":"Early Interv Psychiatry"},{"key":"yoi230041r22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291722001428","article-title":"Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? systematic review and meta-analysis.","author":"Raballo","year":"2022","journal-title":"Psychol Med"},{"issue":"1","key":"yoi230041r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00127-015-1140-0","article-title":"Early psychosis research at Orygen, the National Centre of Excellence in Youth Mental Health.","volume":"51","author":"Cotton","year":"2016","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"yoi230041r24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/eip.2019.13.issue-1","article-title":"Australia\u2019s innovation in youth mental health care: the headspace centre model.","volume":"13","author":"Rickwood","year":"2019","journal-title":"Early Interv Psychiatry"},{"issue":"11-12","key":"yoi230041r25","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","article-title":"Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States.","volume":"39","author":"Yung","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"issue":"6","key":"yoi230041r26","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/schbul\/sbs068","article-title":"The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population.","volume":"38","author":"Ising","year":"2012","journal-title":"Schizophr Bull"},{"issue":"9","key":"yoi230041r27","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1176\/ajp.149.9.1148","article-title":"Revising axis V for DSM-IV: a review of measures of social functioning.","volume":"149","author":"Goldman","year":"1992","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi230041r29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/schbul\/sbm029","article-title":"Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia.","volume":"33","author":"Cornblatt","year":"2007","journal-title":"Schizophr Bull"},{"issue":"3","key":"yoi230041r30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"issue":"4","key":"yoi230041r32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"1-3","key":"yoi230041r33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.schres.2012.12.010","article-title":"Development of the Davos assessment of cognitive biases scale (DACOBS).","volume":"144","author":"van der Gaag","year":"2013","journal-title":"Schizophr Res"},{"issue":"11","key":"yoi230041r34","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"yoi230041r35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.799600","article-title":"Feasibility of an exercise and CBT intervention for treatment of depression: a pilot randomized controlled trial.","volume":"13","author":"Meyer","year":"2022","journal-title":"Front Psychiatry"},{"issue":"2","key":"yoi230041r36","article-title":"Treatment fidelity over the last decade in psychosocial clinical trials outcome studies: a systematic review.","volume":"18","author":"Prowse","year":"2015","journal-title":"J Psychiatry"},{"issue":"4","key":"yoi230041r37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/10669817.2015.1135555","article-title":"Consideration of treatment fidelity to improve manual therapy research.","volume":"24","author":"Karas","year":"2016","journal-title":"J Man Manip Ther"},{"issue":"1","key":"yoi230041r38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/21642850.2020.1738935","article-title":"Focusing on fidelity: narrative review and recommendations for improving intervention fidelity within trials of health behaviour change interventions.","volume":"8","author":"Toomey","year":"2020","journal-title":"Health Psychol Behav Med"},{"issue":"4","key":"yoi230041r39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/eip.v16.4","article-title":"Cannabidiol for at risk for psychosis youth: a randomized controlled trial.","volume":"16","author":"Amminger","year":"2022","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"yoi230041r40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14728222.2021.1849144","article-title":"Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.","volume":"25","author":"Sonnenschein","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"yoi230041r41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/138161212799316163","article-title":"Neuroprotective effects of low-dose lithium in individuals at ultrahigh risk for psychosis. a longitudinal MRI\/MRS study.","volume":"18","author":"Berger","year":"2012","journal-title":"Curr Pharm Des"},{"key":"yoi230041r43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/d41573-019-00033-8","article-title":"Massive NIH-industry project opens portals to target validation.","volume":"18","author":"Dolgin","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"yoi230041r44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.biopsych.2020.05.027","article-title":"Collaborative approaches to the clinical high-risk state: from data to mechanism to intervention.","volume":"88","author":"Gordon","year":"2020","journal-title":"Biol Psychiatry"},{"issue":"10","key":"yoi230041r45","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/s41562-021-01195-5","article-title":"Searching for active ingredients to combat youth anxiety and depression.","volume":"5","author":"Sebastian","year":"2021","journal-title":"Nat Hum Behav"},{"key":"yoi230041r46","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3389\/fpsyt.2018.00502","article-title":"Recent meta-analyses in the clinical high risk for psychosis population: clinical interpretation of findings and suggestions for future research.","volume":"9","author":"Nelson","year":"2018","journal-title":"Front Psychiatry"},{"issue":"2","key":"yoi230041r47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/wps.v17.2","article-title":"Beyond the \u201cat risk mental state\u201d concept: transitioning to transdiagnostic psychiatry.","volume":"17","author":"McGorry","year":"2018","journal-title":"World Psychiatry"},{"key":"yoi230041r48","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3389\/fpsyt.2020.00488","article-title":"Commentary: preventive treatments for psychosis: umbrella review (just the evidence).","volume":"11","author":"Nelson","year":"2020","journal-title":"Front Psychiatry"},{"key":"yoi230041r28","volume-title":"The PACE clinic manual: a treatment approach for young people at ultra high risk of psychosis","author":"The PACE Manual Writing Group","year":"2012"},{"key":"yoi230041r31","volume-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"yoi230041r21","unstructured":"Orygen. Treating Depression in Young People: Guidance, Resources and Tools for Assessment and Management. Published 2017. https:\/\/www.orygen.org.au\/Skills-Knowledge\/Resources-Training\/Resources\/Free\/Clinical-Practice\/Treating-depression-in-young-people-Guidance,-res\/orygen_Clinical_practice_guide_depression_in_young.aspx?ext=."},{"key":"yoi230041r42","unstructured":"National Institutes of Health. Accelerating medicines partnership program\u2014schizophrenia. Accessed May 24, 2023. https:\/\/www.ampscz.org"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2806605\/jamapsychiatry_mcgorry_2023_oi_230041_1693497175.48315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:07:47Z","timestamp":1694012867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2806605"}},"subtitle":["The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.1947","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}